Cardinal Health (CAH) closed the most recent trading day at $107.03, moving +1.84% from the previous trading session. This move outpaced the S&P 500's daily loss of 1.2%. Meanwhile, the Dow experienced a drop of 0.65%, and the technology-dominated Nasdaq saw a decrease of 1.79%.The prescription drug distributor's stock has dropped by 4.98% in the past month, exceeding the Medical sector's loss of 6.57% and lagging the S&P 500's loss of 0.85%.Market participants will be closely following the financial result ...

Cardinal Health - CPI是用来衡量通货膨胀和通货紧缩率的指标[1] - CPI数据发布后，市场会有正面或负面的反应[2] - Cardinal Health是一家领先的医疗保健分销商，股价在过去一年上涨了33%[5] - Cardinal Health在2024财年第二季度报告中，总收入同比增长12%，净收入从负1.3亿美元增长到3.54亿美元[6] - CAH提高了2024全年的盈利预期，预计每股收益在7.20美元至7.35美元之间[7] Forestar Group - Forestar Group是一家专门从事住宅用地开发的房地产公司，股价在过去一年翻了一番[11] - Forestar在2024财年第一季度报告中，总收入增长了41%，净收入同比增长了84%[12] - Forestar预计2024全年收入将达到14亿至15亿美元，预计交付约1.5万个住宅用地[14] Blue Owl Capital - Blue Owl Capital是一家投资公司，股价在过去一年上涨了23%，提供9.59%的年度股息率[16] - Blue Owl Capital在2023财年第四季度报告中，总投资收入增长了14%，净收入同比略有下降[18]

Cardinal Health (CAH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this prescription drug distributor have returned -3.2%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Medical - Dental Supplies industry, which Cardinal falls in, has lost 0.4%. The key question now is: What could be the stock ...

股价表现 - Cardinal Health (CAH) 最近的股价为 $109.47，较前一个交易日下跌了 -0.41% [1] - Cardinal Health 过去一个月的股价下跌了 4.56%，落后于医疗行业的下跌幅度为 0.6% 和标普500指数的上涨幅度为 2.57% [2] 财务预测 - Cardinal Health 即将发布财报，预计每股收益为 $1.96，同比增长 12.64%，营收预计为 $55.82 亿美元，同比增长 10.56% [3][4] - Zacks Consensus Estimates 预计全年每股收益为 $7.28，营收为 $226.9 亿美元，同比增长分别为 +25.73% 和 +10.68% [5] 评级和指标 - Cardinal Health 的 Zacks Rank 为 2 (Buy)，显示分析师对公司的业务健康和盈利能力持乐观态度 [8] - Cardinal Health 目前的前瞻市盈率为 15.09，低于行业平均值 18.49 [9] - CAH 目前的 PEG 比率为 1.06，略低于医疗 - 牙科用品行业的平均 PEG 比率 1.8 [10] 行业排名 - 医疗 - 牙科用品行业属于医疗行业，目前的 Zacks Industry Rank 为 81，在 250 多个行业中排名前 33% [11] - Zacks Industry Rank 衡量了行业群体的实力，研究表明排名前 50% 的行业胜过后 50% 的行业 [12] 监控工具 - 使用 Zacks.com 监控所有这些影响股票的指标，以及更多信息 [13]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Cardinal Health (CAH) , which belongs to the Zacks Medical - Dental Supplies industry, could be a great candidate to consider.When looking at the last two reports, this prescription drug distributor has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 20.12%, on average, in the last two quarters.For the las ...

公司业务 - Cardinal Health Inc. (CAH)因其收购驱动的策略、多元化产品组合和强劲的制药业务而处于增长的有利位置[1] - CAH市值为271亿美元，是一家全国性的药品分销商和服务提供商，预计未来五年盈利将增长14.3%[2] - 公司于2023年12月宣布推出SmartGown EDGE Breathable Surgical Gown，以提供手术团队在手术室内安全便捷的仪器访问[4] - 公司于2023年9月宣布推出Kangaroo OMNI Enteral Feeding Pump，旨在为肠内喂养患者提供更多选择，满足其个性化需求[5] - 公司于2024年1月宣布已达成协议，以12亿美元现金收购Specialty Networks，这将为独立专科提供者和合作伙伴创造临床和经济价值[10] 市场表现 - 投资者对Cardinal Health的医疗和制药产品组合持乐观态度，这为公司在利基领域获得竞争优势[3] - 投资者对Cardinal Health在过去几个月在战略地区开设几家分销中心持乐观态度[6] - 公司于2023年12月宣布计划在南卡罗来纳州格林维尔建立新的分销中心，以支持其At-Home Solutions业务[7] - Cardinal Health Canada宣布计划在大多伦多地区开设新的分销中心，以更好地满足加拿大医疗和外科产品需求[8] - Cardinal Health继续面临支持销售的高成本和不断上升的运营费用，这可能在2024财年上半年对利润率造成影响[11] 财务展望 - Cardinal Health令人印象深刻的2024财年第二季度业绩增强了乐观情绪，公司的制药业务表现强劲[9] - Cardinal Health的Monoject注射器在FDA的不利建议下受到负面影响，可能引发担忧[12] - Zacks对2024财年Cardinal Health的营收预期为226.9亿美元，较上一年水平提高10.7%[13] - 股票分析师建议关注DaVita Inc. (DVA)、Stryker (SYK)和Cencora, Inc. (COR)等其他医疗领域的优秀股票[14]

投资增长股 - 投资者寻找增长股，以利用金融领域的高于平均增长，帮助这些证券吸引市场关注并产生异常回报[1] - 利用Zacks Growth Style Score可以轻松找到前沿增长股，该评分系统超越传统增长属性，分析公司的真实增长前景[3] - Cardinal Health (CAH)是一家公司，我们的专有系统目前推荐的股票之一，不仅具有有利的增长评分，还具有顶级的Zacks Rank[4] 公司增长指标 - Cardinal的每股收益预计今年将增长25.8%，远超行业平均水平，这是一个重要的增长指标[7] - Cardinal的资产利用率比行业平均水平高，公司每资产1美元可以获得4.88美元的销售额[9] - Cardinal的销售预计今年将增长10.7%，远超行业平均水平，这也是一个重要的增长指标[10] - Cardinal的当年盈利预期已经上调，过去一个月Zacks对当年的盈利预期上涨了0.1%[12] 公司表现优势 - Cardinal根据多个因素（包括上述因素）获得了A级的Growth Score，这使得公司在表现上处于有利地位，增长投资者可能会选择押注在它身上[13]

Investors care about the bottom line. What does this mean? Well, we want to be looking for companies that are making a profit and growing their earnings at an appealing rate over time. There’s not much appeal in investing in a company that doesn’t have great prospects for improving its earnings. It’s also not too enticing to put our money in a company that can make great revenue but can’t manage to hang on to any of it after all of its costs.Although there are occasions when it can be crucial for companies ...

Zacks Premium - Zacks Premium提供了多种方式帮助投资者更加聪明和自信地投资[1] Zacks Style Scores - Zacks Style Scores是一种辅助指标，与Zacks Rank一起评估股票，根据价值、增长和动量特征对股票进行评级[3] VGM Score - VGM Score结合了三种Style Scores，帮助找到具有最具吸引力价值、最佳增长预测和最有前景动量的公司[8] Style Scores与Zacks Rank结合使用 - Style Scores与Zacks Rank结合使用，选择具有Zacks Rank 1或2且Style Scores为A或B的股票，以确保最大的上涨潜力[12] Cardinal Health (CAH) - Cardinal Health (CAH)是一家总部位于俄亥俄州都柏林的全国性药品分销商，具有Zacks Rank 2 (Buy)和VGM Score为A[15] - CAH具有优秀的动量和VGM Style Scores，应该被列入投资者的观察名单[18]

DUBLIN, Ohio, March 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels. "We are committed to reducing our impact on the environment and contributing to a more ...